Literature DB >> 31141789

The changing landscape of interventional cardiology.

Richard J Jabbour1, Azeem Latib2,3,4.   

Abstract

Entities:  

Keywords:  aortic stenosis; transcatheter aortic valve implantation

Mesh:

Year:  2019        PMID: 31141789      PMCID: PMC6555454          DOI: 10.18632/aging.102005

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


× No keyword cloud information.
Transcatheter aortic valve replacement (TAVR) has changed the landscape of interventional cardiology and is now the treatment of choice for patients with severe aortic stenosis and elevated surgical risk [1]. TAVR was once a procedure deemed only suitable for non-surgical extreme risk patients, but since the first implantation in 2002, several hundred thousand procedures have been performed worldwide and randomized studies have now reported the superiority of TAVR over conventional open heart surgery, even in low risk surgical patients [1,2]. Whilst early procedures were commonly associated with severe periprocedural complications and protracted in-hospital stays, operator familiarity and equipment design improvements have drastically improved outcomes. For example, lower profile devices and delivery systems, pre-operative computed tomography, and improvements in vascular closure devices have now made TAVR a “minimal” procedure with many patients often discharged after an overnight stay [3]. However, due to the intrinsic nature of TAVR, and the displacement of the old diseased valve by the new percutaneously implanted valve, certain complications including ostial coronary artery obstruction continue to persist and are often deadly with mortality rates of up to 50% [4]. It is generally recognised to occur acutely during the index procedure and predominantly because of obstruction of the coronary ostia by the displaced native valve leaflets and classically in patients with high risk features (previous bioprosthetic valve, narrow sinuses of Valsalva, low coronary heights) [4]. Recently however, data were reported from a large registry (consisting of 18 international centres and data from 17,092 TAVR procedures over 11 years) regarding delayed coronary obstruction (DCO), a new complication in which the coronary obstruction occurs after the index procedure and in some cases months and years after the index procedure [5]. The reported incidence was low (0.22%, n=38) but this may well be under-reported; for example, if sudden cardiac death was the first manifestation of DCO, it may go undiagnosed if no autopsy is performed. Additionally, patients would be protected from DCO if they have had prior coronary artery bypass surgery. The finding and description of DCO is important since originally TAVR was implanted in high or extreme risk patients with relatively low survival rates (up to 30% mortality at 1 year in high risk surgical patients). This means that patients could have died prior to the development of DCO. As understandably cardiologists and patients are keen to continue embracing TAVR over conventional surgery and there is a drive to implant in lower surgical risk patients, it is important to reflect and gather data on this new phenomenon. Since the publication of the original report, there have been concerns raised that DCO may even be the structural equivalent of the feared complication of late stent thrombosis (seen 1-12 months post implantation), that was deadly and discovered only after drug eluting stents had been rapidly adopted throughout the world (1-2% incidence with mortality rate of up to 50%) [6]. However, it must be stated that the incidence of DCO from the multicentre registry was lower at 0.22% and TAVR clearly has prognostic benefit in the treatment of severe AS. In addition, 2 out of 3 DCO patients had one classical risk factor for acute coronary obstruction (valve-in-valve procedure, narrow sinus of Valsalva, low coronary heights) and therefore was more likely to occur in patients with high-risk anatomies for obstruction. However, since a significant proportion of patients (one third) were not high risk for coronary obstruction, future studies are needed to define new risk factors which could include calcium distribution, leaflet length and morphology. In addition, future generation valves could be designed to minimise obstruction from occurring. The multiple ongoing research studies should specifically define DCO as a recognised complication so that further information can be obtained to monitor the incidence and understand the condition in greater detail.
  5 in total

1.  Delayed Coronary Obstruction After Transcatheter Aortic Valve Implantation is not the Structural Equivalent of Late Stent Thrombosis After Percutaneous Coronary Intervention.

Authors:  Simon Kennon
Journal:  Interv Cardiol       Date:  2018-05

2.  Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients.

Authors:  Michael J Mack; Martin B Leon; Vinod H Thourani; Raj Makkar; Susheel K Kodali; Mark Russo; Samir R Kapadia; S Chris Malaisrie; David J Cohen; Philippe Pibarot; Jonathon Leipsic; Rebecca T Hahn; Philipp Blanke; Mathew R Williams; James M McCabe; David L Brown; Vasilis Babaliaros; Scott Goldman; Wilson Y Szeto; Philippe Genereux; Ashish Pershad; Stuart J Pocock; Maria C Alu; John G Webb; Craig R Smith
Journal:  N Engl J Med       Date:  2019-03-16       Impact factor: 91.245

3.  Delayed Coronary Obstruction After Transcatheter Aortic Valve Replacement.

Authors:  Richard J Jabbour; Akihito Tanaka; Ariel Finkelstein; Michael Mack; Corrado Tamburino; Nicolas Van Mieghem; Ole de Backer; Luca Testa; Pamela Gatto; Paola Purita; Zouhair Rahhab; Verena Veulemans; Anja Stundl; Marco Barbanti; Roberto Nerla; Jan Malte Sinning; Danny Dvir; Giuseppe Tarantini; Molly Szerlip; Werner Scholtz; Smita Scholtz; Didier Tchetche; Fausto Castriota; Christian Butter; Lars Søndergaard; Mohamed Abdel-Wahab; Horst Sievert; Ottavio Alfieri; John Webb; Josep Rodés-Cabau; Antonio Colombo; Azeem Latib
Journal:  J Am Coll Cardiol       Date:  2018-04-10       Impact factor: 24.094

4.  The Vancouver 3M (Multidisciplinary, Multimodality, But Minimalist) Clinical Pathway Facilitates Safe Next-Day Discharge Home at Low-, Medium-, and High-Volume Transfemoral Transcatheter Aortic Valve Replacement Centers: The 3M TAVR Study.

Authors:  David A Wood; Sandra B Lauck; John A Cairns; Karin H Humphries; Richard Cook; Robert Welsh; Jonathon Leipsic; Philippe Genereux; Robert Moss; John Jue; Philipp Blanke; Anson Cheung; Jian Ye; Danny Dvir; Hamed Umedaly; Rael Klein; Kevin Rondi; Rohan Poulter; Dion Stub; Marco Barbanti; Peter Fahmy; Nay Htun; Dale Murdoch; Roshan Prakash; Madeleine Barker; Kevin Nickel; Jay Thakkar; Janarthanan Sathananthan; Ben Tyrell; Faisal Al-Qoofi; James L Velianou; Madhu K Natarajan; Harindra C Wijeysundera; Sam Radhakrishnan; Eric Horlick; Mark Osten; Christopher Buller; Mark Peterson; Anita Asgar; Donald Palisaitis; Jean-Bernard Masson; Susheel Kodali; Tamim Nazif; Vinod Thourani; Vasilis C Babaliaros; David J Cohen; Julie E Park; Martin B Leon; John G Webb
Journal:  JACC Cardiovasc Interv       Date:  2019-03-11       Impact factor: 11.195

5.  Predictive factors, management, and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation: insights from a large multicenter registry.

Authors:  Henrique B Ribeiro; John G Webb; Raj R Makkar; Mauricio G Cohen; Samir R Kapadia; Susheel Kodali; Corrado Tamburino; Marco Barbanti; Tarun Chakravarty; Hasan Jilaihawi; Jean-Michel Paradis; Fabio S de Brito; Sergio J Cánovas; Asim N Cheema; Peter P de Jaegere; Raquel del Valle; Paul T L Chiam; Raúl Moreno; Gonzalo Pradas; Marc Ruel; Jorge Salgado-Fernández; Rogerio Sarmento-Leite; Hadi D Toeg; James L Velianou; Alan Zajarias; Vasilis Babaliaros; Fernando Cura; Antonio E Dager; Ganesh Manoharan; Stamatios Lerakis; Augusto D Pichard; Sam Radhakrishnan; Marco Antonio Perin; Eric Dumont; Eric Larose; Sergio G Pasian; Luis Nombela-Franco; Marina Urena; E Murat Tuzcu; Martin B Leon; Ignacio J Amat-Santos; Jonathon Leipsic; Josep Rodés-Cabau
Journal:  J Am Coll Cardiol       Date:  2013-08-14       Impact factor: 24.094

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.